Literature DB >> 19021069

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients.

Otto Zach, Otto Krieger, Mathilde Foedermayr, Barbara Zellhofer, Dieter Lutz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19021069     DOI： 10.1080/10428190802322893

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

Authors:  François Guilhot; Timothy P Hughes; Jorge Cortes; Brian J Druker; Michele Baccarani; Insa Gathmann; Michael Hayes; Camille Granvil; Yanfeng Wang
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  OCT1 and imatinib transport in CML: is it clinically relevant?

Authors:  D B Watkins; T P Hughes; D L White
Journal:  Leukemia       Date:  2015-07-09       Impact factor: 11.528

Review 3.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

4.  Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.

Authors:  Takeru Nambu; Akinobu Hamada; Reiko Nakashima; Misato Yuki; Tatsuya Kawaguchi; Hiroaki Mitsuya; Hideyuki Saito
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

5.  Differences in the substrate binding regions of renal organic anion transporters 1 (OAT1) and 3 (OAT3).

Authors:  Bethzaida Astorga; Theresa M Wunz; Mark Morales; Stephen H Wright; Ryan M Pelis
Journal:  Am J Physiol Renal Physiol       Date:  2011-05-04

Review 6.  Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors:  C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal:  Pharmacogenomics J       Date:  2015-11-03       Impact factor: 3.550

Review 7.  Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.

Authors:  Mohamed A M Ali
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

8.  The pharmacogenetics of imanitib.

Authors:  Stéphanie Dulucq; Maja Krajinovic
Journal:  Genome Med       Date:  2010-11-30       Impact factor: 11.117

9.  Role of OCT1 in hepatocellular carcinoma.

Authors:  Jingguo Li; Zhengyi Yang; Biguang Tuo
Journal:  Onco Targets Ther       Date:  2019-07-25       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.